Luna-Gutiérrez, M.; Hernández-RamÃrez, R.; Soto-Abundiz, A.; GarcÃa-Pérez, O.; Ancira-Cortez, A.; López-Buenrostro, S.; Gibbens-Bandala, B.; Soldevilla-Gallardo, I.; Lara-Almazán, N.; Rojas-Pérez, M.;
et al. Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses. Pharmaceutics 2023, 15, 1988.
https://doi.org/10.3390/pharmaceutics15071988
AMA Style
Luna-Gutiérrez M, Hernández-RamÃrez R, Soto-Abundiz A, GarcÃa-Pérez O, Ancira-Cortez A, López-Buenrostro S, Gibbens-Bandala B, Soldevilla-Gallardo I, Lara-Almazán N, Rojas-Pérez M,
et al. Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses. Pharmaceutics. 2023; 15(7):1988.
https://doi.org/10.3390/pharmaceutics15071988
Chicago/Turabian Style
Luna-Gutiérrez, Myrna, Rodrigo Hernández-RamÃrez, Airam Soto-Abundiz, Osvaldo GarcÃa-Pérez, Alejandra Ancira-Cortez, Sergio López-Buenrostro, Brenda Gibbens-Bandala, Irma Soldevilla-Gallardo, Nancy Lara-Almazán, Melissa Rojas-Pérez,
and et al. 2023. "Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses" Pharmaceutics 15, no. 7: 1988.
https://doi.org/10.3390/pharmaceutics15071988
APA Style
Luna-Gutiérrez, M., Hernández-RamÃrez, R., Soto-Abundiz, A., GarcÃa-Pérez, O., Ancira-Cortez, A., López-Buenrostro, S., Gibbens-Bandala, B., Soldevilla-Gallardo, I., Lara-Almazán, N., Rojas-Pérez, M., Ocampo-GarcÃa, B., AzorÃn-Vega, E., Santos-Cuevas, C., & Ferro-Flores, G.
(2023). Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses. Pharmaceutics, 15(7), 1988.
https://doi.org/10.3390/pharmaceutics15071988
